Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
07/2001
07/24/2001US6265547 Polypeptide for use in diagnosis, treatment, and prevention of cancer, nervous system disorders
07/24/2001US6265546 Polypeptide; for diagnosis and treatment of cancer; anticarcinogenic agents
07/24/2001US6265544 Adipocyte-specific protein homologs
07/24/2001US6265543 Polypeptide for the treatment of eye disorders, tumors, cancer, psoriasis, trauma, psychological, burns and ulcers
07/24/2001US6265541 Uses of α-conotoxin peptides
07/24/2001US6265540 Peptide having specific amino acid sequence which is cleavage site for prostate specific antigen proteolytic activity; antiproliferative agents
07/24/2001US6265536 Cyclic hexapeptides having antibiotic activity
07/24/2001US6265535 Cyclic peptide; for drug screening of antagonists; antiinflammatory agents; treatment of cachexia, malaria, autoimmune disorders, septic shock, skin allergies, and graft versus host disease
07/24/2001US6265534 Superpotent calcitonin analogs having greatly increased hypocalcemic action in vivo
07/24/2001US6265390 Methods for expressing nucleic acid sequences using nucleic acid constructs comprising hypoxia response elements
07/24/2001US6265388 Antisense inhibition of angiogenin expression
07/24/2001US6265384 Non-volatile surfactants, polar organic compounds, non-volatile fatty alcohols, or non-volatile fatty esters, for a time sufficient to trigger the immersion reflex in said ectoparasites
07/24/2001US6265382 Dipeptide inhibitors of protein farnesyltransferase
07/24/2001US6265381 Morpholinourea and related derivatives of pentafluoroethyl peptides
07/24/2001US6265380 Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
07/24/2001US6265379 Local administration of a neurotoxin; botulinum toxin administered to myoclonic middle ear muscles and inner ear efferent and/or afferent nerves to alleviate otic disorders such as tinnitus and cochlear nerve dysfunction
07/24/2001US6265378 Protein Z-dependent protease inhibitor
07/24/2001US6265377 Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
07/24/2001US6265375 Conformationally constrained backbone cyclized peptide analogs
07/24/2001US6265374 Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
07/24/2001US6265218 Introducing promoter and heterologous dna encoding a product into plasmid containing antibiotic resistance selection marker, amplifying, using restriction enzymes to form two fragments, cyclizing to form separate plasmids
07/24/2001US6265216 Antisense modulation of cot oncogene expression
07/24/2001US6265215 Isolated peptides which complex with HLA-Cw16 and uses thereof
07/24/2001US6265214 Methods and compositions for inducing monocyte cytotoxicity
07/24/2001US6265195 Nucleic acid of defined nucleotide sequence which codes for a deoxyribonuclease; for production of enough enzyme for clinical use; diagnosis; treatment of cystic fibrosis, lupus, chronic bronchitis, pneumonia, emphysema, and asthma
07/24/2001US6265192 Glycosly sulfortransferase-3
07/24/2001US6265189 Expressing polypeptide in cell culture; insert gene into viral expression vector, transform cells, recover preferential polypeptide
07/24/2001US6265188 Nucleotide sequence coding a enzymatic polypeptide; for use as a wound healing agent; for prevention of bacterial infection
07/24/2001US6265187 Recombinant endotoxin-neutralizing proteins
07/24/2001US6265184 Polynucleotides encoding chemokine receptor 88C
07/24/2001US6265173 Methods of modulating the expression of genes using ultraspiracle receptor
07/24/2001US6265160 Method of identifying inhibitors of the Jak-Stat signal transduction pathway
07/24/2001US6265158 Nucleotide sequences associated with genetic disorders; for the detection and diagnosis of preferential genetic disorders
07/24/2001US6265149 Screening sample for preferential immunological complexes; incubate sample with antigen, incubate sample with control, monitor complexes formed, count complexes in samples, more complexes in antigen sample indicates presence of retrovirus
07/24/2001US6265147 Detecting modulators of brain activity; mix modulator with receptors and detect activation of receptors
07/24/2001US6264990 Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity.
07/24/2001US6264988 Reduce bleeding time in animal
07/24/2001US6264955 Ferrichrome transport ATP-binding protein
07/24/2001US6264953 Method of preparation and use for zona pellucida antigens and antibodies for sterilization and contraception
07/24/2001US6264951 Administering polypeptide
07/24/2001US6264948 Methods and compositions for inhibiting tumor cell growth
07/24/2001US6264947 Genetic engineering; therapy for cancer, autoimmune diseases, reproduction, antiinflammatory agents
07/24/2001US6264945 Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
07/24/2001US6264943 Parkinson's disease
07/24/2001US6264941 Compositions for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
07/24/2001US6264917 Targeted ultrasound contrast agents
07/24/2001CA2331847A1 Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors
07/24/2001CA2230303C Polymorphs of the prodrug 6-n-(l-ala-l-ala)-trovafloxacin
07/24/2001CA2193454C Bioadhesive pharmaceutical composition for the controlled release of active ingredients
07/24/2001CA2191844C Acylated enol derivatives as prodrugs of elastase inhibitors
07/24/2001CA2092652C Antiherpes peptide derivatives having a ureido n-terminus
07/24/2001CA2085465C Thrombin inhibitors based on the amino acid sequence of hirudin
07/24/2001CA2065299C Direct radiolabeling of antibodies and other proteins with technetium or rhenium
07/24/2001CA2058676C Process for isolating human albumin from supernatant iv, in particular iv-4, or from cohn's fraction v or from an analogous supernatant or fraction
07/24/2001CA2027936C Cyclic anti-aggregatory peptides
07/24/2001CA2024629C Xenopus laevis bone morphogenic protein, dna encoding same and use thereof
07/19/2001WO2001051673A1 Methods and compositions for inhibition of membrane fusion-associated events, including hiv transmission
07/19/2001WO2001051651A2 High expression and production of high-specific activity recombinant s-adenosyl homocysteinase (sahh) and improved assays for s-adenosylmethionine (sam)
07/19/2001WO2001051645A1 Obg3 globular head and uses thereof for decreasing body mass
07/19/2001WO2001051642A2 Dna modification proteins
07/19/2001WO2001051641A1 Irak-4: compositions and methods of use
07/19/2001WO2001051640A2 Regulation of human mitochondrial transformylase
07/19/2001WO2001051638A2 Drug metabolizing enzymes
07/19/2001WO2001051636A2 Secreted proteins
07/19/2001WO2001051635A2 Novel stra6 polypeptides
07/19/2001WO2001051633A2 Compositions and methods for the therapy and diagnosis of prostate cancer
07/19/2001WO2001051632A2 Odorant receptor polypeptides and nucleic acids encoding same
07/19/2001WO2001051630A1 Antisense compositions and methods
07/19/2001WO2001051624A2 Carboxypeptidase b free of animal products and contaminating enyzme activity
07/19/2001WO2001051609A1 Isolation and in vitro differentiation of conditionally immortalized murine olfactory receptor neurons
07/19/2001WO2001051608A2 Hybrid cells obtainable from antigen presenting cells
07/19/2001WO2001051523A2 Anti-angiogenic proteins and fragments and methods of use thereof
07/19/2001WO2001051520A2 Nogo receptor-mediated blockade of axonal growth
07/19/2001WO2001051518A2 Nucleic acids encoding human semaphorin proteins and use thereof
07/19/2001WO2001051513A2 Ovarian tumor-associated sequences
07/19/2001WO2001051512A2 Human and parasite orphan receptor proteins
07/19/2001WO2001051511A2 Recombinant production of human histone-1 subtypes and use thereof for therapeutic purposes
07/19/2001WO2001051510A2 G-csf conjugates
07/19/2001WO2001051509A2 Shc-associated protein 140 (sap-140)
07/19/2001WO2001051508A1 Peptide inhibitors of lfa-1/icam-1 interaction
07/19/2001WO2001051504A1 71 human secreted proteins
07/19/2001WO2001051503A1 Polynucleotides for inhibiting metastasis and tumor cell growth
07/19/2001WO2001051487A1 Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
07/19/2001WO2001051462A1 INHIBITORS OF THE ICE/Ced-3 FAMILY OF CYSTEINE PROTEASES
07/19/2001WO2001051454A1 Compounds and compositions for delivering active agents
07/19/2001WO2001051093A2 METHODS OF INCREASING THE GLUCOSE RESPONSIVENESS OF PANCREATIC β-CELLS
07/19/2001WO2001051085A1 Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease
07/19/2001WO2001051081A1 In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent
07/19/2001WO2001051080A2 Methods and compositions for obtaining disease protection for animals
07/19/2001WO2001051079A1 Antigen-specific ige antibody production inhibitors
07/19/2001WO2001051078A1 Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
07/19/2001WO2001051077A1 Methods of regulating il-12 production by administering ccr5 agonists and antagonists
07/19/2001WO2001051075A1 Enhancing lymph channel development and treatment of lymphatic obstructive disease
07/19/2001WO2001051074A1 Methods for treating pancreatic disorders
07/19/2001WO2001051073A2 The parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
07/19/2001WO2001051072A2 Antiparasitic agent
07/19/2001WO2001051071A2 Transepithelial delivery of glp-1 derivatives
07/19/2001WO2001051067A1 Multiple inactivated blood factor anticoagulant composition
07/19/2001WO2001051049A1 O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
07/19/2001WO2001051037A1 Osmotic device containing diltiazem and an ace inhibitor or diuretic